Clinical Trial Update: CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy. [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating CD19/BCMA CAR T-cells, including universal allogeneic CAR T-cells, in autoimmune hemolytic anemia patients who have faile…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• CD19/BCMA CAR T-cells

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Autoimmune Hemolytic Anemia, CD19/BCMA CAR T-cells | Phase 1 | Status: RECRUITING